Trial reportCancer discovery2018
Abstract readClinical Trial, Phase IIIRandomized Controlled Trial
In one paragraph
Trial report in Cancer discovery, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1,092 papers, 2 of them syntheses that pooled it.
0numbers the graph read from it
0cells of the map it votes in
1,092citing papers in PubMed, 2 pooled it
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1,092 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Immunotherapy for TKI-resistant, EGFR L858R-mutated non-small cell lung cancer: a systematic review and meta-analysis of randomized and single-arm studies.Frontiers in immunology · 2026Pooled it
- A meta-analysis of experimentally validated neo-epitopes: patterns, biases, and opportunities.Cancer immunology, immunotherapy : CII · 2025Pooled it
- Trial
- Evaluation of Biomarkers for Sacituzumab Govitecan in Metastatic Non-Small Cell Lung Cancer: Insights From the EVOKE-01 Study.Cancer research communications · 2026Trial
- LRP1b Loss Predicts Sensitivity to Immunotherapy in Patients with NSCLC: An Analysis of the Phase III CheckMate-026 Randomized Trial.Clinical cancer research : an official journal of the American Association for Cancer Research · 2025Trial
- Non-small cell lung cancer molecular subtypes and vulnerability to immunotherapy treatment combinations.Nature communications · 2025Trial
- The Immune Checkpoint Inhibitors Journey: From Early Promise to Lasting Impact.Journal of immunotherapy and precision oncology · 2026Review
- Co-mutation patterns and survival associations in lung cancer: a comparative analysis of Swedish and global cohorts.Acta oncologica (Stockholm, Sweden) · 2026Article
- PRTN3 drives immunosuppression in KRAS-mutant lung adenocarcinoma through proteolytic inactivation of CXCL9.Journal for immunotherapy of cancer · 2026Article
- Utilizing Machine Learning to Identify Multimodal Signatures for Patients Who Would Benefit from the Addition of Tremelimumab to Durvalumab and Chemotherapy (TRIDENT).Clinical cancer research : an official journal of the American Association for Cancer Research · 2026Observational
- Clinical Outcomes Associated with Single STK11 Mutations and Those Co-occurring with KEAP1 and KRAS Mutations in Metastatic Non-Small Cell Lung Cancer.Advances in therapy · 2026Article
- Review
- Targeting the Tumor Microenvironment Network to Overcome Immunotherapy Resistance in Non-Small Cell Lung Cancer: Mechanisms to Clinical Translation.Cancer medicine · 2026Review
- Impact of differentTranslational lung cancer research · 2026Article
- Molecular insights and therapeutic implications for the tumor suppressor role of LKB1 in non-small cell lung cancer.Cancer letters · 2026Review
- Immune-pressure redistribution in resistance to PD-1/PD-L1 blockade: mechanisms, biomarkers, and therapeutic design.Molecular cancer · 2026Review
- Targeting LKB1-inactivated lung cancers with a stapled peptide inhibitor of the CRTC-CREB pathway.Molecular therapy. Oncology · 2026Article
- Multimodal Artificial Intelligence in Lung Cancer: From Data Integration to Precision Oncology.Cancers · 2026Review
- Mutant p53 sensitizes KRAS-driven lung adenocarcinoma to immunotherapy by repressing SPP1.Science advances · 2026Article
- Beyond KRASG12C: emerging therapeutic strategies, patent landscape, and clinical progress in targeting KRAS-mutant cancers.Medical oncology (Northwood, London, England) · 2026Review
1,032 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
Authors and funding
69 authors.
Ferdinandos Skoulidis *Department of Thoracic and Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Michael E Goldberg *Foundation Medicine Inc., Cambridge, Massachusetts.ORCID 0000-0003-3310-6349
Danielle M Greenawalt *Bristol-Myers Squibb Co., Princeton, New Jersey.
Matthew D HellmannDruckenmiller Center for Lung Cancer Research and Department of Medicine, Thoracic Oncology Service, Memorial Sloan Kettering Cancer Center, New York, New York.
Mark M AwadLowe Center for Thoracic Oncology and Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.
Justin F GainorDepartment of Medicine, Massachusetts General Hospital, Boston, Massachusetts.
Alexa B SchrockFoundation Medicine Inc., Cambridge, Massachusetts.
Ryan J HartmaierFoundation Medicine Inc., Cambridge, Massachusetts.
Sally E TrabuccoFoundation Medicine Inc., Cambridge, Massachusetts.
Laurie GayFoundation Medicine Inc., Cambridge, Massachusetts.
Siraj M AliFoundation Medicine Inc., Cambridge, Massachusetts.
Julia A ElvinFoundation Medicine Inc., Cambridge, Massachusetts.
Gaurav SingalFoundation Medicine Inc., Cambridge, Massachusetts.
Jeffrey S RossFoundation Medicine Inc., Cambridge, Massachusetts.
David FabrizioFoundation Medicine Inc., Cambridge, Massachusetts.
Peter M SzaboBristol-Myers Squibb Co., Princeton, New Jersey.
Han ChangBristol-Myers Squibb Co., Princeton, New Jersey.
Ariella SassonBristol-Myers Squibb Co., Princeton, New Jersey.
Sujaya SrinivasanBristol-Myers Squibb Co., Princeton, New Jersey.
Stefan KirovBristol-Myers Squibb Co., Princeton, New Jersey.
Joseph SzustakowskiBristol-Myers Squibb Co., Princeton, New Jersey.
Patrik VitazkaBristol-Myers Squibb Co., Princeton, New Jersey.
Robin EdwardsBristol-Myers Squibb Co., Princeton, New Jersey.
Jose A BufillMichiana Hematology Oncology, Mishawaka, Indiana.
Neelesh SharmaNovartis Institute of Biomedical Research, East Hanover, New Jersey.
Sai-Hong I OuChao Family Comprehensive Cancer Center, University of California, Irvine, Orange, California.
Nir PeledThoracic Cancer Unit, Davidoff Cancer Center, Petach Tiqwa, Israel.
David R SpigelSarah Cannon Research Institute, Nashville, Tennessee.
Hira RizviDruckenmiller Center for Lung Cancer Research and Department of Medicine, Thoracic Oncology Service, Memorial Sloan Kettering Cancer Center, New York, New York.
Elizabeth Jimenez AguilarLowe Center for Thoracic Oncology and Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.
Brett W CarterDepartment of Diagnostic Radiology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Jeremy ErasmusDepartment of Diagnostic Radiology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Darragh F HalpennyDepartment of Radiology, Memorial Sloan Kettering Cancer Center, New York, New York.
Andrew J PlodkowskiDepartment of Radiology, Memorial Sloan Kettering Cancer Center, New York, New York.ORCID 0000-0002-3772-370X
Niamh M LongDepartment of Radiology, Memorial Sloan Kettering Cancer Center, New York, New York.
Mizuki NishinoDepartment of Radiology, Brigham and Women's Hospital and Dana-Farber Cancer Institute, Boston, Massachusetts.
Warren L DenningDepartment of Thoracic and Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Ana Galan-CoboDepartment of Thoracic and Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Haifa HamdiDepartment of Thoracic and Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Taghreed HirzDepartment of Thoracic and Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Pan TongDepartment of Bioinformatics and Computational Biology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Jing WangDepartment of Bioinformatics and Computational Biology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Jaime Rodriguez-CanalesDepartment of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Pamela A VillalobosDepartment of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Edwin R ParraDepartment of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Neda KalhorDepartment of Pathology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Lynette M ShollDepartment of Pathology, Brigham and Women's Hospital, Boston, Massachusetts.
Jennifer L SauterDepartment of Pathology, Memorial Sloan Kettering Cancer Center, New York, New York.
Achim A JungbluthDepartment of Pathology, Memorial Sloan Kettering Cancer Center, New York, New York.
Mari Mino-KenudsonDepartment of Pathology, Massachusetts General Hospital, Boston, Massachusetts.
Roxana AzimiDepartment of Medicine, Massachusetts General Hospital, Boston, Massachusetts.
Yasir Y ElaminDepartment of Thoracic and Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Jianjun ZhangDepartment of Thoracic and Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Giulia C LeonardiLowe Center for Thoracic Oncology and Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.
Fei JiangDepartment of Statistics and Actuarial Science, The University of Hong Kong, Hong Kong, China.
Kwok-Kin WongPerlmutter Cancer Center, NYU Langone Medical Center, New York, New York.
J Jack LeeDepartment of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Vassiliki A PapadimitrakopoulouDepartment of Thoracic and Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Ignacio I WistubaDepartment of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Vincent A MillerFoundation Medicine Inc., Cambridge, Massachusetts.
Garrett M FramptonFoundation Medicine Inc., Cambridge, Massachusetts.
Jedd D WolchokLudwig Center for Cancer Immunotherapy, Memorial Sloan Kettering Cancer Center, New York, New York.
Alice T ShawDepartment of Medicine, Massachusetts General Hospital, Boston, Massachusetts.
Pasi A JänneLowe Center for Thoracic Oncology and Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.
Philip J StephensFoundation Medicine Inc., Cambridge, Massachusetts.
Charles M RudinDruckenmiller Center for Lung Cancer Research and Department of Medicine, Thoracic Oncology Service, Memorial Sloan Kettering Cancer Center, New York, New York.
William J GeeseBristol-Myers Squibb Co., Princeton, New Jersey.
Lee A AlbackerFoundation Medicine Inc., Cambridge, Massachusetts. jheymach@mdanderson.org lalbacker@foundationmedicine.com.ORCID 0000-0002-5070-1783
John V HeymachDepartment of Thoracic and Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas. jheymach@mdanderson.org lalbacker@foundationmedicine.com.ORCID 0000-0001-9068-8942
Funding
X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Nicholas D Socci · 1985 to 2026
$347.4MTumor Evolution and Metastasis ProgramP30CA016672 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI Scott Kopetz · 1985 to 2026
$290.8MUNIVERSITY OF TEXAS--SPORE IN LUNG CANCERP50CA070907 · NCI · UT SOUTHWESTERN MEDICAL CENTER · PI GIBBONS, DON LYNN · 1996 to 2024
$57.4MMUC1-C Oncoprotein Evades Immune Destruction in Non-small Cell Lung CancerR01CA166480 · NCI · DANA-FARBER CANCER INST · PI KUFE, DONALD W., WONG, KWOK KIN · 2012 to 2021
$6.3MTherapeutic strategies for specific subsets of KRAS mutant lung cancersR01CA140594 · NCI · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · PI WONG, KWOK KIN · 2009 to 2017
$4.5MTherapeutic approaches for LKB1-deficient non-small cell lung cancerR01CA205150 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI HEYMACH, JOHN V., WONG, KWOK KIN · 2016 to 2020
$3.0MAutomated in vivo analysis of tumor growth rate as a guide for therapeutic decisions to advance personalized cancer treatmentR01CA203636 · NCI · BRIGHAM AND WOMEN'S HOSPITAL · PI NISHINO, MIZUKI · 2017 to 2021
$2.9MCredentialing Mouse Models for Immune System Therapy ResearchR01CA195740 · NCI · UNIV OF NORTH CAROLINA CHAPEL HILL · PI PEROU, CHARLES M, WONG, KWOK KIN · 2015 to 2017
$1.8MNCI NIH HHS P30 CA008748NCI NIH HHS P30 CA016672NCI NIH HHS P50 CA070907NCI NIH HHS R01 CA140594NCI NIH HHS R01 CA166480NCI NIH HHS R01 CA195740NCI NIH HHS R01 CA203636NCI NIH HHS R01 CA205150
Abstract
PubMed holds no abstract for this paper.
Indexed as
MutationAdenocarcinoma of LungAdultAgedAged, 80 and overAMP-Activated Protein Kinase KinasesAnimalsAntineoplastic Agents, ImmunologicalDisease Models, AnimalDrug Resistance, NeoplasmHumansImmunotherapyLung NeoplasmsMaleMiceMiddle AgedAMP-Activated Protein Kinase KinasesAntineoplastic Agents, ImmunologicalKRAS protein, humanNivolumabProgrammed Cell Death 1 ReceptorProtein Serine-Threonine KinasesProto-Oncogene Proteins p21(ras)STK11 protein, human
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.